Eli Lilly sues two pharmacies making copycat Zepbound, Mounjaro

Eli Lilly sues two pharmacies making copycat Zepbound, Mounjaro


The Eli Lilly logo is shown on one of the company’s offices in San Diego, California, on Sept. 17, 2020.

Mike Blake | Reuters

Eli Lilly is suing two pharmacies for compounding Zepbound and Mounjaro, claiming the companies are skirting the Food and Drug Administration’s ban on the practice and luring people away from Lilly’s medicines.

In lawsuits filed Tuesday in Delaware and New Jersey, Lilly alleges the two companies — Strive Pharmacy and Empower Pharmacy — are falsely marketing their products as personalized versions of the drugs that have been clinically tested and are made using stringent safety standards. Lilly argues these claims are turning people toward compounded drugs and away from its FDA-approved treatments.

Strive and Empower didn’t immediately respond to CNBC’s requests for comment.

Compounding pharmacies and outsourcing facilities were largely supposed to stop making their own versions of tirzepatide, the active ingredient in Lilly’s weight-loss drug Zepbound and diabetes treatment Mounjaro, last month after the FDA determined the branded versions were no longer in shortage. Some continued compounding, tweaking the dosages and combining them with vitamins, distinctions that make them different from Lilly’s drugs and potentially allow them to skirt the FDA’s ban.

An injection pen of Zepbound, Eli Lilly’s weight loss drug, is displayed in New York City on Dec. 11, 2023.

Brendan McDermid | Reuters

Lilly argues Strive and Empower are merely mass producing altered versions of tirzepatide rather than personalizing them. Branded drugs are allowed to be compounded at large scale when they’re in shortage. Outside of that, custom versions can be made for unique situations, like if a person is allergic to an ingredient or can’t take the form of the drug it’s normally sold in.

Strive and Empower supply tirzepatide to popular telehealth sites, including Lavender Sky Health and Mochi Health. The companies didn’t immediately respond to CNBC’s requests for comment.

These lawsuits will be the first test of Lilly’s ability to take on compounding pharmacies in court now that Zepbound and Mounjaro are off the FDA’s shortage list. And they could provide a roadmap for Novo Nordisk, whose obesity drug Wegovy and diabetes treatment Ozempic generally can’t be compounded after the end of May.



Source

Supreme Court endorses Obamacare panel that requires free preventive care
Health

Supreme Court endorses Obamacare panel that requires free preventive care

Demonstrators in support of U.S. President Barack Obama’s health-care law, the Affordable Care Act (ACA), hold up ‘ACA is Here to Stay’ signs after the U.S. Supreme Court ruled 6-3 to save Obamacare tax subsidies outside the Supreme Court in Washington, D.C. June 25, 2015. Andrew Harrer | Bloomberg | Getty Images WASHINGTON — The […]

Read More
Supreme Court rules for South Carolina over bid to defund Planned Parenthood
Health

Supreme Court rules for South Carolina over bid to defund Planned Parenthood

Planned Parenthood signage is displayed outside of a health care clinic in Los Angeles, California on May 16, 2023.  Patrick T. Fallon | AFP | Getty Images WASHINGTON — The Supreme Court on Thursday ruled for South Carolina over its effort to defund Planned Parenthood, concluding that individual Medicaid patients cannot sue to enforce their […]

Read More
Healthy Returns: New weight loss drug data show Eli Lilly is gaining ground
Health

Healthy Returns: New weight loss drug data show Eli Lilly is gaining ground

A sign with the company logo sits outside of the headquarters of Eli Lilly in Indianapolis, Indiana, on March 17, 2024. Scott Olson | Getty Images A version of this article first appeared in CNBC’s Healthy Returns newsletter, which brings the latest health-care news straight to your inbox. Subscribe here to receive future editions. Competition in […]

Read More